$ALOT
AstroNova, Inc.

2015 Q2 Form 10-Q Financial Statement

#000119312515206051 Filed on May 29, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2014 Q2
Revenue $22.21M $20.77M
YoY Change 6.89% 34.16%
Cost Of Revenue $13.18M $12.14M
YoY Change 8.54% 25.04%
Gross Profit $9.030M $8.635M
YoY Change 4.57% 69.15%
Gross Profit Margin 40.66% 41.57%
Selling, General & Admin $5.786M $5.565M
YoY Change 3.97% 18.05%
% of Gross Profit 64.08% 64.45%
Research & Development $1.796M $1.371M
YoY Change 31.0% 23.18%
% of Gross Profit 19.89% 15.88%
Depreciation & Amortization $455.0K $512.0K
YoY Change -11.13% 65.16%
% of Gross Profit 5.04% 5.93%
Operating Expenses $7.582M $6.936M
YoY Change 9.31% 19.03%
Operating Profit $1.448M $1.699M
YoY Change -14.77% -335.32%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $234.0K -$121.0K
YoY Change -293.39% 236.11%
Pretax Income $1.682M $1.578M
YoY Change 6.59% -308.18%
Income Tax $471.0K $449.0K
% Of Pretax Income 28.0% 28.45%
Net Earnings $1.211M $1.129M
YoY Change 7.26% -351.45%
Net Earnings / Revenue 5.45% 5.43%
Basic Earnings Per Share $0.17 $0.15
Diluted Earnings Per Share $0.16 $0.14
COMMON SHARES
Basic Shares Outstanding 7.280M shares 7.601M shares
Diluted Shares Outstanding 7.454M shares 7.848M shares

Balance Sheet

Concept 2015 Q2 2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.70M $28.60M
YoY Change -13.64% -11.46%
Cash & Equivalents $8.815M $10.14M
Short-Term Investments $15.80M $18.50M
Other Short-Term Assets $8.800M $7.500M
YoY Change 17.33% -39.02%
Inventory $14.49M $16.18M
Prepaid Expenses
Receivables $14.01M $12.84M
Other Receivables $400.0K $500.0K
Total Short-Term Assets $62.36M $65.60M
YoY Change -4.93% 0.45%
LONG-TERM ASSETS
Property, Plant & Equipment $8.678M $7.563M
YoY Change 14.74% -0.49%
Goodwill $991.0K $991.0K
YoY Change 0.0%
Intangibles $2.609M $3.224M
YoY Change -19.08%
Long-Term Investments
YoY Change
Other Assets $3.835M $500.0K
YoY Change 667.0% 0.0%
Total Long-Term Assets $12.51M $5.120M
YoY Change 144.39% -46.11%
TOTAL ASSETS
Total Short-Term Assets $62.36M $65.60M
Total Long-Term Assets $12.51M $5.120M
Total Assets $74.88M $78.28M
YoY Change -4.35% 4.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.065M $2.480M
YoY Change 63.91% 12.73%
Accrued Expenses $2.143M $6.000M
YoY Change -64.28% 7.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.239M $8.919M
YoY Change 3.59% -0.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $200.0K
YoY Change -100.0%
Other Long-Term Liabilities $1.100M $1.000M
YoY Change 10.0% -23.08%
Total Long-Term Liabilities $1.100M $1.200M
YoY Change -8.33% -7.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.239M $8.919M
Total Long-Term Liabilities $1.100M $1.200M
Total Liabilities $10.40M $10.19M
YoY Change 2.01% -11.38%
SHAREHOLDERS EQUITY
Retained Earnings $40.43M $37.80M
YoY Change 6.98%
Common Stock $478.0K $473.0K
YoY Change 1.06%
Preferred Stock
YoY Change
Treasury Stock (at cost) $19.59M $13.09M
YoY Change 49.65%
Treasury Stock Shares 2.294M shares 1.776M shares
Shareholders Equity $64.48M $68.09M
YoY Change
Total Liabilities & Shareholders Equity $74.88M $78.28M
YoY Change -4.35% 4.65%

Cashflow Statement

Concept 2015 Q2 2014 Q2
OPERATING ACTIVITIES
Net Income $1.211M $1.129M
YoY Change 7.26% -351.45%
Depreciation, Depletion And Amortization $455.0K $512.0K
YoY Change -11.13% 65.16%
Cash From Operating Activities $2.970M -$2.495M
YoY Change -219.04% -64.22%
INVESTING ACTIVITIES
Capital Expenditures $654.0K $292.0K
YoY Change 123.97% 158.41%
Acquisitions
YoY Change
Other Investing Activities -$1.170M $4.460M
YoY Change -126.23% -138.48%
Cash From Investing Activities -$1.820M $4.169M
YoY Change -143.66% -135.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -370.0K 125.0K
YoY Change -396.0% -196.15%
NET CHANGE
Cash From Operating Activities 2.970M -2.495M
Cash From Investing Activities -1.820M 4.169M
Cash From Financing Activities -370.0K 125.0K
Net Change In Cash 780.0K 1.799M
YoY Change -56.64% -109.57%
FREE CASH FLOW
Cash From Operating Activities $2.970M -$2.495M
Capital Expenditures $654.0K $292.0K
Free Cash Flow $2.316M -$2.787M
YoY Change -183.1% -60.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2012Q1 alot Debt Received Upon Sale Of Operation
DebtReceivedUponSaleOfOperation
1000000
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7307255 shares
CY2014Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10140000
CY2015Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9593005 shares
CY2015Q2 us-gaap Loans Receivable Basis Spread On Variable Rate
LoansReceivableBasisSpreadOnVariableRate
0.02 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
9.71
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
13000000 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.53
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
443977 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.03
CY2015Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
2293606 shares
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
69982 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
722940 shares
CY2015Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3478000
CY2015Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
28823000
CY2015Q2 us-gaap Liabilities Current
LiabilitiesCurrent
9239000
CY2015Q2 us-gaap Common Stock Value
CommonStockValue
478000
CY2015Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-709000
CY2015Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
4065000
CY2015Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
40434000
CY2015Q2 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
105000
CY2015Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2143000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
64481000
CY2015Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
74877000
CY2015Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
791000
CY2015Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
43869000
CY2015Q2 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
1052000
CY2015Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
546000
CY2015Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
633000
CY2015Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
59000
CY2015Q2 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
10000000
CY2015Q2 us-gaap Liabilities
Liabilities
10396000
CY2015Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2426000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8815000
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
278000
CY2015Q2 us-gaap Goodwill
Goodwill
991000
CY2015Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
9487000
CY2015Q2 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
250000
CY2015Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8678000
CY2015Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
600000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2601468
CY2015Q2 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
18246000
CY2015Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3652000
CY2015Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2609000
CY2015Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7229000
CY2015Q2 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
131000
CY2015Q2 us-gaap Notes Receivable Net
NotesReceivableNet
375000
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
278000
CY2015Q2 us-gaap Inventory Land Held For Sale
InventoryLandHeldForSale
1900000
CY2015Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
37501000
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2260318
CY2015Q2 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
104000
CY2015Q2 us-gaap Assets
Assets
74877000
CY2015Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
2409000
CY2015Q2 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
2640000
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
349000
CY2015Q2 us-gaap Inventory Gross
InventoryGross
17966000
CY2015Q2 us-gaap Inventory Net
InventoryNet
14488000
CY2015Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
14012000
CY2015Q2 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
15837000
CY2015Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2609000
CY2015Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1250000
CY2015Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3835000
CY2015Q2 us-gaap Treasury Stock Value
TreasuryStockValue
19591000
CY2015Q2 us-gaap Assets Current
AssetsCurrent
62364000
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
268000
CY2015Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
331000
CY2015Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3400000
CY2015Q2 alot Revolving Line Of Credit Facility Issued Maximum Capacity
RevolvingLineOfCreditFacilityIssuedMaximumCapacity
600000
CY2015Q2 alot Product Replacement Cost Charged Against Reserve
ProductReplacementCostChargedAgainstReserve
338000
CY2015Q2 alot Revolving Line Of Credit Facility Issued Amount Outstanding
RevolvingLineOfCreditFacilityIssuedAmountOutstanding
170000
CY2015Q2 alot Amount Of Reserve For Settlement Of Liability
AmountOfReserveForSettlementOfLiability
334000
CY2015Q2 alot Line Of Credit Receivable Current
LineOfCreditReceivableCurrent
170000
CY2015Q2 alot Fixed Charge Coverage Ratio
FixedChargeCoverageRatio
3 pure
CY2015Q2 alot Funded Debt To Adjusted Ebitda Ratio
FundedDebtToAdjustedEbitdaRatio
1.25 pure
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8341000
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9544864 shares
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
13000000 shares
CY2015Q1 us-gaap Treasury Stock Shares
TreasuryStockShares
2293606 shares
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.05
CY2015Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
3155000
CY2015Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
28444000
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
9569000
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
477000
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-699000
CY2015Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3155000
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
39735000
CY2015Q1 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
83000
CY2015Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2343000
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
63511000
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
74330000
CY2015Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
702000
CY2015Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
43589000
CY2015Q1 us-gaap Liability For Uncertain Tax Positions Noncurrent
LiabilityForUncertainTaxPositionsNoncurrent
1167000
CY2015Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
621000
CY2015Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
707000
CY2015Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
148000
CY2015Q1 us-gaap Liabilities
Liabilities
10819000
CY2015Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3302000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7958000
CY2015Q1 us-gaap Goodwill
Goodwill
991000
CY2015Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
10600000
CY2015Q1 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
255000
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8379000
CY2015Q1 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
18202000
CY2015Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4140000
CY2015Q1 us-gaap Deferred Tax Assets Net Current
DeferredTaxAssetsNetCurrent
2629000
CY2015Q1 us-gaap Inventory Gross
InventoryGross
18737000
CY2015Q1 us-gaap Inventory Net
InventoryNet
15582000
CY2015Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
14107000
CY2015Q1 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
15174000
CY2015Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2698000
CY2015Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
765000
CY2015Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
4033000
CY2015Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2698000
CY2015Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7372000
CY2015Q1 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
256000
CY2015Q1 us-gaap Inventory Land Held For Sale
InventoryLandHeldForSale
1900000
CY2015Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
36823000
CY2015Q1 us-gaap Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
88000
CY2015Q1 us-gaap Assets
Assets
74330000
CY2015Q1 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
3028000
CY2015Q1 us-gaap Treasury Stock Value
TreasuryStockValue
19591000
CY2015Q1 us-gaap Assets Current
AssetsCurrent
61918000
CY2015Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3400000
CY2015Q1 alot Line Of Credit Receivable Current
LineOfCreditReceivableCurrent
173000
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
9.70
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.01
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
72245 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
656011 shares
CY2015Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-699000
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7958000
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3225000
CY2012Q1 alot Loan Receivable Interest Rate Stated Percentage
LoanReceivableInterestRateStatedPercentage
0.0375 pure
CY2014Q1 alot Settlement Amount Received From Supplier For Recovery Of Cost And Expenses
SettlementAmountReceivedFromSupplierForRecoveryOfCostAndExpenses
450000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y2M12D
CY2013Q2 alot Estimated Replacement Cost Of Product
EstimatedReplacementCostOfProduct
672000
CY2015Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.16
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
2800 shares
CY2015Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.12
CY2015Q2 dei Document Type
DocumentType
10-Q
CY2015Q2 dei Entity Registrant Name
EntityRegistrantName
ASTRO MED INC /NEW/
CY2015Q2 dei Trading Symbol
TradingSymbol
ALOT
CY2015Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
173936 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.43
CY2015Q2 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2015Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.280 pure
CY2015Q2 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>(1) Overview</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Headquartered in West Warwick, Rhode Island, Astro-Med Inc. designs, develops, manufactures and distributes a broad range of specialty printers and data acquisition and analysis systems. Our products are distributed through our own sales force and authorized dealers in the United States. We also sell to customers outside of the United States primarily through our Company offices in Canada, Europe and Southeast Asia as well as with independent dealers and representatives. Astro-Med, Inc. products are sold under the brand names Astro-Med&#xA0;<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;Test&#xA0;&amp; Measurement and QuickLabel&#xA0;<sup style="FONT-SIZE: 11px; VERTICAL-ALIGN: top">&#xAE;</sup>&#xA0;Systems and are employed around the world in a wide range of aerospace, apparel, automotive, avionics, chemical, computer peripherals, communications, distribution, food and beverage, general manufacturing, packaging and transportation applications.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> Unless otherwise indicated, references to &#x201C;Astro-Med,&#x201D; the &#x201C;Company,&#x201D; &#x201C;we,&#x201D; &#x201C;our,&#x201D; and &#x201C;us&#x201D; in this Quarterly Report on Form&#xA0;10-Q refer to Astro-Med, Inc. and its consolidated subsidiaries.</p> </div>
CY2015Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
2972000
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
13.95
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
0 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.020 pure
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2015Q2 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2016-01-31
CY2015Q2 us-gaap Line Of Credit Facility Expiration Period
LineOfCreditFacilityExpirationPeriod
P3Y
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
85000 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
537 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.016 pure
CY2015Q2 dei Document Period End Date
DocumentPeriodEndDate
2015-05-02
CY2015Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
8.55
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
0
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
10.07
CY2015Q2 dei Amendment Flag
AmendmentFlag
false
CY2015Q2 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--01-31
CY2015Q2 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2015Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7454000 shares
CY2015Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.17
CY2015Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
207000
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y4M24D
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
2293 shares
CY2015Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
13.95
CY2015Q2 dei Entity Central Index Key
EntityCentralIndexKey
0000008146
CY2015Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.07
CY2015Q2 us-gaap Line Of Credit Facility Interest Rate Description
LineOfCreditFacilityInterestRateDescription
Any borrowings made under this line of credit bear interest at either a fluctuating base rate equal to the highest of (i) the Prime Rate, (ii) 1.50% above the daily one month LIBOR, and (iii) the Federal Funds Rate in effect plus 1.50% or at a fixed rate of LIBOR plus an agreed upon margin of between 0% and 2.25%, based on the Company's funded debt to EBITDA ratio as defined in the agreement.
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.227 pure
CY2015Q2 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
76200 shares
CY2015Q2 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 Segment
CY2015Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
15778 shares
CY2015Q2 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2015Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7280000 shares
CY2015Q2 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
3127000
CY2015Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
8000
CY2015Q2 us-gaap Increase In Restricted Cash
IncreaseInRestrictedCash
600000
CY2015Q2 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
-93000
CY2015Q2 us-gaap Gross Profit
GrossProfit
9030000
CY2015Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4329000
CY2015Q2 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
268000
CY2015Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-10000
CY2015Q2 us-gaap Sales Revenue Net
SalesRevenueNet
22206000
CY2015Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
234000
CY2015Q2 us-gaap Line Of Credit Facility Average Outstanding Amount
LineOfCreditFacilityAverageOutstandingAmount
0
CY2015Q2 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1094000
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1682000
CY2015Q2 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
510000
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1448000
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1201000
CY2015Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
234000
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1682000
CY2015Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
654000
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
1211000
CY2015Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-95000
CY2015Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-18000
CY2015Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
455000
CY2015Q2 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
79000
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
7582000
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1796000
CY2015Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
89000
CY2015Q2 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
857000
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
471000
CY2015Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
13176000
CY2015Q2 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-373000
CY2015Q2 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1821000
CY2015Q2 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
143000
CY2015Q2 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
10000
CY2015Q2 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2015Q2 us-gaap Other Than Temporary Impairment Losses Investments Availableforsale Securities
OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities
0
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1457000
CY2015Q2 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-397000
CY2015Q2 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
137000
CY2015Q2 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
2435000
CY2015Q2 us-gaap Share Based Compensation
ShareBasedCompensation
143000
CY2015Q2 us-gaap Proceeds From Sale And Collection Of Notes Receivable
ProceedsFromSaleAndCollectionOfNotesReceivable
125000
CY2015Q2 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
135000
CY2015Q2 alot Non Employee Director Received Restricted Stock Award Value
NonEmployeeDirectorReceivedRestrictedStockAwardValue
20000
CY2015Q2 alot Fees To Non Employee Director
FeesToNonEmployeeDirector
7000
CY2015Q2 alot Loan Receivable Date Considered For Interest Payments
LoanReceivableDateConsideredForInterestPayments
2013-01-30
CY2015Q2 alot Number Of Equity Incentive Plans
NumberOfEquityIncentivePlans
1 Equity_Plan
CY2015Q2 alot Maximum Disposal Restriction As Percentage Of Restricted Stock Units
MaximumDisposalRestrictionAsPercentageOfRestrictedStockUnits
0.50 pure
CY2015Q2 alot Number Of Installments
NumberOfInstallments
16 Installment
CY2015Q2 alot Reservation Of Shares Under Employee Stock Purchase Plan
ReservationOfSharesUnderEmployeeStockPurchasePlan
247500 shares
CY2015Q2 alot Period To Receive Lower Product Prices From Supplier Description
PeriodToReceiveLowerProductPricesFromSupplierDescription
Through fiscal 2017
CY2014Q1 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
779000
CY2015Q1 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
220000
CY2014Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.14
CY2014Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
247520 shares
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.93
CY2014Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.285 pure
CY2014Q2 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2495000
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.020 pure
CY2014Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.016 pure
CY2014Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7848000 shares
CY2014Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.15
CY2014Q2 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0.07
CY2014Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.268 pure
CY2014Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
75600 shares
CY2014Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7601000 shares
CY2014Q2 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
2574000
CY2014Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
92000
CY2014Q2 us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
735000
CY2014Q2 us-gaap Gross Profit
GrossProfit
8635000
CY2014Q2 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1471000
CY2014Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
89000
CY2014Q2 us-gaap Sales Revenue Net
SalesRevenueNet
20774000
CY2014Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-121000
CY2014Q2 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1003000
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1578000
CY2014Q2 us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
533000
CY2014Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
1699000
CY2014Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1218000
CY2014Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-121000
CY2014Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
1578000
CY2014Q2 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
292000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
1129000
CY2014Q2 us-gaap Decrease In Restricted Cash
DecreaseInRestrictedCash
1800000
CY2014Q2 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
125000
CY2014Q2 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
4169000
CY2014Q2 us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
131000
CY2014Q2 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
59000
CY2014Q2 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
166000
CY2014Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3000
CY2014Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
512000
CY2014Q2 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-91000
CY2014Q2 us-gaap Operating Expenses
OperatingExpenses
6936000
CY2014Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1371000
CY2014Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4374000
CY2014Q2 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-731000
CY2014Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
175000
CY2014Q2 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1799000
CY2014Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
449000
CY2014Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
12139000
CY2014Q2 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2014Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1191000
CY2014Q2 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1691000
CY2014Q2 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
658000
CY2014Q2 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
2880000
CY2014Q2 us-gaap Share Based Compensation
ShareBasedCompensation
131000
CY2014Q2 us-gaap Tax Adjustments Settlements And Unusual Provisions
TaxAdjustmentsSettlementsAndUnusualProvisions
100000
CY2014Q2 alot Proceeds From Disposition Of Inventory
ProceedsFromDispositionOfInventory
2355000

Files In Submission

Name View Source Status
0001193125-15-206051-index-headers.html Edgar Link pending
0001193125-15-206051-index.html Edgar Link pending
0001193125-15-206051.txt Edgar Link pending
0001193125-15-206051-xbrl.zip Edgar Link pending
alot-20150502.xml Edgar Link completed
alot-20150502.xsd Edgar Link pending
alot-20150502_cal.xml Edgar Link unprocessable
alot-20150502_def.xml Edgar Link unprocessable
alot-20150502_lab.xml Edgar Link unprocessable
alot-20150502_pre.xml Edgar Link unprocessable
d922924d10q.htm Edgar Link pending
d922924dex101.htm Edgar Link pending
d922924dex102.htm Edgar Link pending
d922924dex311.htm Edgar Link pending
d922924dex312.htm Edgar Link pending
d922924dex321.htm Edgar Link pending
d922924dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending